S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.91 (+1.43%)
AAPL   122.80 (+3.15%)
MSFT   216.20 (+1.00%)
FB   286.50 (+3.44%)
GOOGL   1,796.09 (+2.38%)
AMZN   3,222.60 (+1.72%)
TSLA   585.14 (+3.09%)
NVDA   535.72 (-0.06%)
BABA   264.00 (+0.24%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.60 (-0.06%)
T   28.89 (+0.49%)
NIO   45.31 (-10.33%)
F   9.23 (+1.65%)
ACB   9.90 (-15.24%)
NFLX   504.78 (+2.87%)
BA   213.28 (+1.22%)
GILD   61.11 (+0.73%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.91 (+1.43%)
AAPL   122.80 (+3.15%)
MSFT   216.20 (+1.00%)
FB   286.50 (+3.44%)
GOOGL   1,796.09 (+2.38%)
AMZN   3,222.60 (+1.72%)
TSLA   585.14 (+3.09%)
NVDA   535.72 (-0.06%)
BABA   264.00 (+0.24%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.60 (-0.06%)
T   28.89 (+0.49%)
NIO   45.31 (-10.33%)
F   9.23 (+1.65%)
ACB   9.90 (-15.24%)
NFLX   504.78 (+2.87%)
BA   213.28 (+1.22%)
GILD   61.11 (+0.73%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.91 (+1.43%)
AAPL   122.80 (+3.15%)
MSFT   216.20 (+1.00%)
FB   286.50 (+3.44%)
GOOGL   1,796.09 (+2.38%)
AMZN   3,222.60 (+1.72%)
TSLA   585.14 (+3.09%)
NVDA   535.72 (-0.06%)
BABA   264.00 (+0.24%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.60 (-0.06%)
T   28.89 (+0.49%)
NIO   45.31 (-10.33%)
F   9.23 (+1.65%)
ACB   9.90 (-15.24%)
NFLX   504.78 (+2.87%)
BA   213.28 (+1.22%)
GILD   61.11 (+0.73%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.91 (+1.43%)
AAPL   122.80 (+3.15%)
MSFT   216.20 (+1.00%)
FB   286.50 (+3.44%)
GOOGL   1,796.09 (+2.38%)
AMZN   3,222.60 (+1.72%)
TSLA   585.14 (+3.09%)
NVDA   535.72 (-0.06%)
BABA   264.00 (+0.24%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.60 (-0.06%)
T   28.89 (+0.49%)
NIO   45.31 (-10.33%)
F   9.23 (+1.65%)
ACB   9.90 (-15.24%)
NFLX   504.78 (+2.87%)
BA   213.28 (+1.22%)
GILD   61.11 (+0.73%)
DIS   149.09 (+0.73%)
Log in
NASDAQ:ABMD

Abiomed Stock Forecast, Price & News

$268.38
-5.72 (-2.09 %)
(As of 12/1/2020 03:59 PM ET)
Add
Compare
Today's Range
$264.39
Now: $268.38
$274.32
50-Day Range
$251.88
MA: $272.23
$290.51
52-Week Range
$119.01
Now: $268.38
$319.19
Volume12,405 shs
Average Volume540,961 shs
Market Capitalization$12.13 billion
P/E Ratio58.98
Dividend YieldN/A
Beta1.42
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Abiomed logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400
Employees1,536

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$840.88 million
Cash Flow$5.36 per share
Book Value$26.17 per share

Profitability

Net Income$203.01 million

Miscellaneous

Market Cap$12.13 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$268.38
-5.72 (-2.09 %)
(As of 12/1/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abiomed (NASDAQ:ABMD) Frequently Asked Questions

How has Abiomed's stock price been impacted by COVID-19 (Coronavirus)?

Abiomed's stock was trading at $151.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABMD shares have increased by 78.4% and is now trading at $269.65.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Abiomed?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Abiomed
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Abiomed?

Wall Street analysts have given Abiomed a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abiomed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Abiomed
.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) released its earnings results on Tuesday, November, 3rd. The medical equipment provider reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.87 by $0.49. The medical equipment provider had revenue of $209.80 million for the quarter, compared to analyst estimates of $202.89 million. Abiomed had a return on equity of 15.34% and a net margin of 25.89%. The firm's quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the company posted $0.28 earnings per share.
View Abiomed's earnings history
.

What guidance has Abiomed issued on next quarter's earnings?

Abiomed issued an update on its third quarter 2021 Pre-Market earnings guidance on Thursday, October, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $221-230 million, compared to the consensus revenue estimate of $234.29 million.

What price target have analysts set for ABMD?

6 Wall Street analysts have issued 12 month target prices for Abiomed's shares. Their forecasts range from $155.00 to $280.00. On average, they expect Abiomed's share price to reach $223.00 in the next twelve months. This suggests that the stock has a possible downside of 17.3%.
View analysts' price targets for Abiomed
.

Who are some of Abiomed's key competitors?

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

Who are Abiomed's key executives?

Abiomed's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 53, Pay $1.68M)
  • Mr. Todd A. Trapp, CFO & VP (Age 49, Pay $800.98k)
  • Dr. David M. Weber, Sr. VP & COO (Age 59, Pay $752.48k)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 56, Pay $522.56k)
  • Mr. Andrew J. Greenfield, VP & Chief Commercial Officer (Age 47, Pay $547.39k)
  • Dr. Thorsten Siess Ph.D., VP & CTO
  • Ms. Ingrid Goldberg Ward, Director of Investor Relations
  • Mr. Marc A. Began, VP, Gen. Counsel & Sec. (Age 53)
  • Ms. Karen Mahoney, Head of Global HR
  • Dr. Charles A. Simonton M.D., VP & Chief Medical Officer

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.76%), State Street Corp (4.33%), Sands Capital Management LLC (3.31%), Jackson Square Partners LLC (1.33%), JPMorgan Chase & Co. (1.26%) and William Blair Investment Management LLC (1.26%). Company insiders that own Abiomed stock include David M Weber, Dorothy E Puhy, Martin P Sutter, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed
.

Which major investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Federated Hermes Inc., Scout Investments Inc., State Street Corp, AXA S.A., Jackson Square Partners LLC, WINTON GROUP Ltd, and Charles Schwab Investment Management Inc.. Company insiders that have sold Abiomed company stock in the last year include Dorothy E Puhy, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed
.

Which major investors are buying Abiomed stock?

ABMD stock was bought by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Wells Fargo & Company MN, First Trust Advisors LP, Voloridge Investment Management LLC, Victory Capital Management Inc., Blair William & Co. IL, Chicago Capital LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Abiomed
.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $269.65.

How big of a company is Abiomed?

Abiomed has a market capitalization of $12.19 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. Abiomed employs 1,536 workers across the globe.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.